How Retatrutide Quiets Food Noise Through Three Mechanisms

"Food noise" is the persistent, intrusive mental chatter about food — thoughts about what to eat next, cravings that surface unprompted, and a background hum of food preoccupation that many people with obesity describe as exhausting. It is not hunger. It is the brain's reward and default mode networks fixating on food even when the body does not need calories.

GLP-1 drugs like semaglutide and tirzepatide are already known to reduce food noise. But retatrutide activates three receptors — GLP-1, GIP, and glucagon — and each one contributes a distinct mechanism to quieting this mental noise. In the Phase 2 obesity trial, 97.2% of retatrutide-treated participants reported changes in appetite or eating behavior, with 100% of those on doses of 4 mg or higher eating less.

Retatrutide is an investigational drug that has not been approved by the FDA.

What Is Food Noise?

Food noise is not a clinical diagnosis. It is a patient-reported experience that researchers have begun to characterize as maladaptive prospection — repetitive, cue-driven mental simulation of short-term food rewards that conflicts with long-term health goals.

The brain's default mode network (DMN), which activates during mind-wandering and accounts for roughly 47% of waking thought, appears to play a central role. When the DMN fixates on food-related scenarios, it creates intrusive, future-oriented thought loops similar to rumination patterns seen in depression.

Key brain regions involved in food noise include:

• Nucleus accumbens — drives cravings and conditioned food responses via dopamine signaling
• Ventral tegmental area (VTA) — the origin of mesolimbic dopamine projections that assign reward value to food
• Insula — processes taste and visceral sensation
• Orbitofrontal cortex — evaluates reward value and drives "wanting"
• Amygdala — assigns emotional salience to food cues

In neuroimaging studies, GLP-1 receptor agonists reduce activation in all of these regions, and the degree of DMN connectivity change correlates with both weight loss and appetite reduction.

Mechanism 1: GLP-1 — Silencing the Reward Pathways

GLP-1 receptor activation is the primary mechanism by which all drugs in this class reduce food noise. GLP-1-producing neurons in the brainstem project directly to the ventral tegmental area and nucleus accumbens — the core of the mesolimbic dopamine reward pathway.

How it works

When GLP-1 receptors in these reward centers are activated, dopamine signaling is dampened. Food becomes less compelling rather than forbidden. Research shows a specific pattern: GLP-1 drugs decrease wanting (anticipatory reward activation) while preserving liking (consummatory pleasure). This is why patients often say "I can still enjoy food, I just don't think about it all day."

GLP-1 receptor activation also:

• Reduces activation in the insula, amygdala, putamen, and orbitofrontal cortex in response to food cues
• Slows gastric emptying, generating peripheral satiety signals that reinforce the central effects
• Modulates glutamatergic neurotransmission in reward circuits

In animal studies, activating GLP-1 in these circuits causes rodents to lose interest in high-fat food. Blocking GLP-1 causes overeating. The same pathway explains why GLP-1 drugs also reduce interest in alcohol, nicotine, and other addictive substances in preclinical models.

The limitation

A Penn Medicine case study published in Nature Medicine (November 2025) implanted intracranial electrodes in the nucleus accumbens of a patient with obesity and loss-of-control eating. After reaching her full dose of tirzepatide, she reported no food preoccupation and her nucleus accumbens activity went silent. However, after approximately 5 months, nucleus accumbens activity returned and food preoccupation broke through — suggesting GLP-1/GIP-based suppression of food noise may be temporary or incomplete in some patients.

This raises the question of whether a third mechanism — one that adds metabolic pressure from a different direction — could produce more durable effects.

Mechanism 2: GIP — Appetite Suppression With Built-In Nausea Protection

The GIP receptor contributes to appetite suppression through a mechanism distinct from GLP-1, and it does so while simultaneously reducing the nausea that limits tolerability of GLP-1 drugs.

GABAergic neuron activation

Single-nuclei RNA sequencing has revealed that GIP receptors are expressed on GABAergic (inhibitory) neurons in the area postrema and nucleus tractus solitarius — brainstem regions that regulate both appetite and nausea. Notably, GIP and GLP-1 receptors sit on distinct populations of neurons in these regions: GIP receptors on inhibitory neurons, GLP-1 receptors on excitatory neurons.

When GIP activates these GABAergic neurons, two things happen simultaneously:

1. Appetite suppression — selective removal of GIP receptors from GABAergic cells eliminates protection against diet-induced obesity and reduces the food intake suppression seen with GIP agonists, especially when co-administered with GLP-1 agonists
2. Anti-nausea buffering — the activated GABAergic neurons suppress nearby excitatory neurons that drive nausea and vomiting responses, including those expressing the GDF15 receptor

Why this matters for food noise

Nausea itself creates a form of food aversion that is distinct from food noise reduction. GLP-1-only drugs reduce food noise but also cause significant nausea (up to 44% with semaglutide 2.4 mg in STEP 1). This nausea can cause patients to reduce doses or discontinue treatment, undermining the food noise benefit.

By buffering nausea while independently suppressing appetite, GIP agonism allows patients to maintain higher effective doses of the GLP-1 component — sustaining the reward pathway silencing without the tolerability penalty.

Mechanism 3: Glucagon — Liver-to-Brain Satiety and Thermogenesis

Glucagon receptor activation is unique to retatrutide among advanced clinical-stage obesity drugs. It adds two mechanisms that neither GLP-1 nor GIP provides.

Liver-brain satiety signaling

Glucagon promotes satiety through a hepatic-portal vagal pathway. When glucagon is sensed in the hepatic-portal vein, it activates vagal afferents that signal the central nervous system. This liver-to-brain axis inhibits meal size — a mechanism that operates independently of the reward pathway suppression driven by GLP-1.

This means retatrutide has two distinct satiety inputs:

1. Top-down — GLP-1 dampens the brain's reward-driven desire for food
2. Bottom-up — glucagon generates a peripheral satiety signal from the liver via the vagus nerve

Energy expenditure and thermogenesis

Glucagon receptor activation also increases energy expenditure through:

• Brown adipose tissue (BAT) thermogenesis — glucagon activates the sympathetic nervous system, which stimulates BAT to burn energy as heat
• Hepatic fatty acid oxidation — the liver burns more fat, reducing liver fat stores
• FGF21 pathway activation — glucagon requires the FGF21 pathway to protect against obesity, leveraging both central and peripheral mechanisms to increase metabolic rate

This thermogenic effect means that retatrutide is not only reducing food intake through three pathways — it is simultaneously increasing the rate at which the body burns energy. The combination may explain why retatrutide produced 24% body weight loss in 48 weeks in Phase 2 trials, compared to 15% with semaglutide (68 weeks) and 22.5% with tirzepatide (72 weeks).

What the Phase 2 Data Shows

Two published analyses from retatrutide Phase 2 trials provide direct evidence of appetite and eating behavior changes.

Eating behavior study (Kanu et al., 2025)

Published in Diabetes, Obesity and Metabolism, this study measured appetite and eating behavior changes in 275 adults with type 2 diabetes treated with retatrutide for 36 weeks.

The disinhibition finding is particularly relevant to food noise — it measures the tendency to overeat in response to food cues, emotional states, or social situations. Retatrutide reduced disinhibition at all doses tested, and the degree of disinhibition reduction correlated with weight loss (r = 0.36, p < 0.005).

Qualitative exit interview study (Goetz et al., 2025)

Published in Obesity Pillars, this study conducted structured exit interviews with 40 participants from the Phase 2 obesity trial (non-diabetic population).

Across all retatrutide-treated participants, 97.2% reported changes in appetite or eating behavior. Notably, 86% reported these changes within the first 8 weeks of treatment. The "different food preferences" finding (82.6%) is consistent with the broader GLP-1 literature on taste changes and food aversions.

Food Aversions and Taste Changes

Up to 70% of people taking GLP-1 medications develop some form of food aversion. While distinct from food noise reduction, these taste changes are part of the broader appetite experience.

Commonly reported changes across GLP-1 drugs include:

• Sweetness perception — about 21% of users report food tasting sweeter
• Saltiness perception — about 23% report food tasting saltier
• Fat aversion — formerly rich foods taste flat or unappetizing
• Protein aversion — some users develop what has been called the "meat ick," particularly with red meat
• Coffee aversion — frequently reported across GLP-1 users

Research published in Physiology & Behavior (2024) found that GLP-1 receptor agonists significantly impair taste function, depressing perception across all five basic taste qualities. These changes are typically most noticeable during initial treatment or dose increases and frequently resolve within 4 to 8 weeks.

Whether retatrutide's triple-agonist mechanism produces a different taste change profile than GLP-1-only or dual-agonist drugs has not been studied directly. The 82.6% of Phase 2 participants reporting "different food preferences" is a signal, but the exit interviews did not characterize the specific nature of those preference changes.

Comparing Appetite Suppression Across Drug Classes

Each generation adds a mechanistic layer. Semaglutide silences reward pathways. Tirzepatide adds the GIP-mediated nausea buffer and GABAergic appetite suppression. Retatrutide adds glucagon-driven liver-brain satiety signaling and energy expenditure — attacking food noise from both the top (brain reward) and the bottom (peripheral metabolism).

Whether this translates to a qualitatively different subjective experience of food noise remains an open question. No head-to-head study has compared food noise scores between these drugs directly.

Frequently Asked Questions

Sources

• Kanu, C., et al. (2025). Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes, Obesity and Metabolism. DOI: 10.1111/dom.70097
• Goetz, I.A., et al. (2025). Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial. Obesity Pillars. DOI: 10.1016/j.obpill.2025.100220
• Holt, M.K., et al. (2025). The role of GIPR in food intake control. Frontiers in Endocrinology. Link
• Borner, T., et al. (2021). GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models. Diabetes. PubMed
• Habegger, K.M., et al. (2022). Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity? Frontiers in Endocrinology. Link
• Mancini, A.D. & Bhatt, D.L. (2019). Glucagon Control on Food Intake and Energy Balance. International Journal of Molecular Sciences. PMC
• D'Souza, M.S. (2025). Quieting "Food Noise": How GLP-1s and Mindfulness Rewire the Default Mode Network (DMN) and Reward Circuits. PMC. Link
• Allison, K., et al. (2025). Tirzepatide may only temporarily quiet "food noise." Nature Medicine. Penn Medicine
• Jastreboff, A.M., et al. (2023). Retatrutide once weekly for treatment of obesity. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
• Dickson, S.L., et al. (2013). The central GLP-1: implications for food and drug reward. Frontiers in Neuroscience. Link

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.

If you are experiencing food noise or disordered eating, consult with your healthcare provider. Do not make changes to your medication based on information about an unapproved drug.

This site is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.